AbbVie Inc. (ABBV) Stock

About AbbVie Inc.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

AbbVie Inc. is led by CEO Robert A. Michael, employs 55,000 people, headquartered in North Chicago, US, publicly traded since 2013.

AbbVie Inc. (ABBV) stock trades at $246.04 with a market capitalization of $434.70B. The stock is valued at a price-to-earnings (P/E) ratio of 127.26, price-to-book of 16.84, price-to-sales of 7.34. Over the past 52 weeks the stock has ranged between $176.11 and $267.21, and currently trades 7.9% below its 52-week high. It pays a dividend yielding 2.58%.

On profitability, AbbVie Inc. generates a return on equity (ROE) of 68.01% — well above the market average, a sign of a high-quality business, return on capital employed of 18.38%, an operating margin of 32.85%, a net profit margin of 5.79%.

In its most recent fiscal year, AbbVie Inc. reported annual revenue of $61.2B, net profit of $4.2B, revenue has compounded at 6.0% a year over the last five years, profit at -1.7% a year.

The balance sheet shows a debt-to-equity ratio of 2.65 — a leveraged balance sheet worth monitoring, a current ratio of 0.67, total assets of $134.0B, $5.2B in cash and equivalents.

ABBV has an average daily trading volume of 6,931,522 shares, a beta of 0.31 (less volatile than the overall market).

Official website: www.abbvie.com